Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development and external validation of a head and neck cancer risk prediction model

CDL. Smith, AD. McMahon, DM. Lyall, M. Goulart, GJ. Inman, A. Ross, M. Gormley, T. Dudding, GJ. Macfarlane, M. Robinson, L. Richiardi, D. Serraino, J. Polesel, C. Canova, W. Ahrens, CM. Healy, P. Lagiou, I. Holcatova, L. Alemany, A. Znoar, T....

. 2024 ; 46 (9) : 2261-2273. [pub] 20240608

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, validační studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019159

Grantová podpora
315941-01 Cancer Research UK - United Kingdom
Italian Ministry of Health "Ricerca Corrente."
825771 European Union's Horizon 2020 research and innovation programme
0180142s08 Estonian Ministry of Education and Research
University of Athens Medical School
Compagnia San Paolo, AIRC
001 World Health Organization - International
QLK1-CT-2001-00182 European Community (5th Framework Programme)

BACKGROUND: Head and neck cancer (HNC) incidence is on the rise, often diagnosed at late stage and associated with poor prognoses. Risk prediction tools have a potential role in prevention and early detection. METHODS: The IARC-ARCAGE European case-control study was used as the model development dataset. A clinical HNC risk prediction model using behavioral and demographic predictors was developed via multivariable logistic regression analyses. The model was then externally validated in the UK Biobank cohort. Model performance was tested using discrimination and calibration metrics. RESULTS: 1926 HNC cases and 2043 controls were used for the development of the model. The development dataset model including sociodemographic, smoking, and alcohol variables had moderate discrimination, with an area under curve (AUC) value of 0.75 (95% CI, 0.74-0.77); the calibration slope (0.75) and tests were suggestive of good calibration. 384 616 UK Biobank participants (with 1177 HNC cases) were available for external validation of the model. Upon external validation, the model had an AUC of 0.62 (95% CI, 0.61-0.64). CONCLUSION: We developed and externally validated a HNC risk prediction model using the ARCAGE and UK Biobank studies, respectively. This model had moderate performance in the development population and acceptable performance in the validation dataset. Demographics and risk behaviors are strong predictors of HNC, and this model may be a helpful tool in primary dental care settings to promote prevention and determine recall intervals for dental examination. Future addition of HPV serology or genetic factors could further enhance individual risk prediction.

Bristol Dental School University of Bristol Bristol United Kingdom

Cancer Epidemiology Unit Department of Medical Sciences University of Turin and CPO Piemonte Turin Italy

Cancer Research UK Scotland Institute Glasgow United Kingdom

Cancer Surveillance Branch International Agency for Research on Cancer Lyon France

Catalan Institute of Oncology IDIBELL Barcelona Spain

Centre for Oral Health Research Newcastle University Newcastle upon Tyne United Kingdom

Deutsches Krebsforschungszentrum Heidelberg Germany

Epidemiology Group School of Medicine Medical Sciences and Nutrition University of Aberdeen Aberdeen United Kingdom

Genomic Epidemiology Group International Agency for Research on Cancer Lyon France

Glasgow Head and Neck Cancer Research Group Glasgow United Kingdom

Institute of Hygiene and Epidemiology 1st Faculty of Medicine Charles University Prague Czech Republic

Leibniz Institute for Prevention Research and Epidemiology BIPS Bremen Germany

School of Cancer Sciences University of Glasgow Glasgow United Kingdom

School of Dental Science Trinity College Dublin Dublin Ireland

School of Health and Wellbeing University of Glasgow Glasgow United Kingdom

School of Health Science and Wellbeing Staffordshire University Staffordshire United Kingdom

School of Medicine Dentistry and Nursing University of Glasgow Glasgow United Kingdom

School of Medicine National and Kapodistrian University of Athens Athens Greece

Unit of Biostatistics Epidemiology and Public Health Department of Cardio Thoraco Vascular Sciences and Public Health University of Padua Padova Italy

Unit of Cancer Epidemiology Centro di Riferimento Oncologico di Aviano IRCCS Aviano Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019159
003      
CZ-PrNML
005      
20241024111723.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hed.27834 $2 doi
035    __
$a (PubMed)38850089
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Smith, Craig D L $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom $u School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom $u Glasgow Head and Neck Cancer (GLAHNC) Research Group, Glasgow, United Kingdom $1 https://orcid.org/0000000164657472
245    10
$a Development and external validation of a head and neck cancer risk prediction model / $c CDL. Smith, AD. McMahon, DM. Lyall, M. Goulart, GJ. Inman, A. Ross, M. Gormley, T. Dudding, GJ. Macfarlane, M. Robinson, L. Richiardi, D. Serraino, J. Polesel, C. Canova, W. Ahrens, CM. Healy, P. Lagiou, I. Holcatova, L. Alemany, A. Znoar, T. Waterboer, P. Brennan, S. Virani, DI. Conway
520    9_
$a BACKGROUND: Head and neck cancer (HNC) incidence is on the rise, often diagnosed at late stage and associated with poor prognoses. Risk prediction tools have a potential role in prevention and early detection. METHODS: The IARC-ARCAGE European case-control study was used as the model development dataset. A clinical HNC risk prediction model using behavioral and demographic predictors was developed via multivariable logistic regression analyses. The model was then externally validated in the UK Biobank cohort. Model performance was tested using discrimination and calibration metrics. RESULTS: 1926 HNC cases and 2043 controls were used for the development of the model. The development dataset model including sociodemographic, smoking, and alcohol variables had moderate discrimination, with an area under curve (AUC) value of 0.75 (95% CI, 0.74-0.77); the calibration slope (0.75) and tests were suggestive of good calibration. 384 616 UK Biobank participants (with 1177 HNC cases) were available for external validation of the model. Upon external validation, the model had an AUC of 0.62 (95% CI, 0.61-0.64). CONCLUSION: We developed and externally validated a HNC risk prediction model using the ARCAGE and UK Biobank studies, respectively. This model had moderate performance in the development population and acceptable performance in the validation dataset. Demographics and risk behaviors are strong predictors of HNC, and this model may be a helpful tool in primary dental care settings to promote prevention and determine recall intervals for dental examination. Future addition of HPV serology or genetic factors could further enhance individual risk prediction.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory hlavy a krku $x epidemiologie $7 D006258
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a logistické modely $7 D016015
650    _2
$a rizikové faktory $7 D012307
651    _2
$a Spojené království $x epidemiologie $7 D006113
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a McMahon, Alex D $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom $1 https://orcid.org/0000000294257792
700    1_
$a Lyall, Donald M $u School of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom $1 https://orcid.org/0000000338501487
700    1_
$a Goulart, Mariel $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom $1 https://orcid.org/0000000152636746
700    1_
$a Inman, Gareth J $u School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom $u Glasgow Head and Neck Cancer (GLAHNC) Research Group, Glasgow, United Kingdom $u Cancer Research UK Scotland Institute, Glasgow, United Kingdom $1 https://orcid.org/0000000262644253
700    1_
$a Ross, Al $u School of Health, Science and Wellbeing, Staffordshire University, Staffordshire, United Kingdom $1 https://orcid.org/0000000329523182
700    1_
$a Gormley, Mark $u Bristol Dental School, University of Bristol, Bristol, United Kingdom $1 https://orcid.org/0000000157336304
700    1_
$a Dudding, Tom $u Bristol Dental School, University of Bristol, Bristol, United Kingdom $1 https://orcid.org/000000033756040X
700    1_
$a Macfarlane, Gary J $u Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom $1 https://orcid.org/0000000323223314
700    1_
$a Robinson, Max $u Centre for Oral Health Research, Newcastle University, Newcastle upon Tyne, United Kingdom $1 https://orcid.org/0000000344916865
700    1_
$a Richiardi, Lorenzo $u Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy $1 https://orcid.org/0000000303169402
700    1_
$a Serraino, Diego $u Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
700    1_
$a Polesel, Jerry $u Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy $1 https://orcid.org/0000000193811520
700    1_
$a Canova, Cristina $u Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padova, Italy $1 https://orcid.org/0000000170277935
700    1_
$a Ahrens, Wolfgang $u Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany $1 https://orcid.org/000000033777570X $7 nlk20050169817
700    1_
$a Healy, Claire M $u School of Dental Science, Trinity College Dublin, Dublin, Ireland $1 https://orcid.org/0000000305836360
700    1_
$a Lagiou, Pagona $u School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Holcatova, Ivana $u Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000213660337 $7 jo2002105437
700    1_
$a Alemany, Laia $u Catalan Institute of Oncology/IDIBELL, Barcelona, Spain $1 https://orcid.org/0000000309456015
700    1_
$a Znoar, Ariana $u Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
700    1_
$a Waterboer, Tim $u Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
700    1_
$a Brennan, Paul $u Genomic Epidemiology Group, International Agency for Research on Cancer, Lyon, France $1 https://orcid.org/0000000205188714
700    1_
$a Virani, Shama $u Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France $u Genomic Epidemiology Group, International Agency for Research on Cancer, Lyon, France $1 https://orcid.org/000000021163432X
700    1_
$a Conway, David I $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom $u Glasgow Head and Neck Cancer (GLAHNC) Research Group, Glasgow, United Kingdom $1 https://orcid.org/0000000177624063
773    0_
$w MED00001983 $t Head & neck $x 1097-0347 $g Roč. 46, č. 9 (2024), s. 2261-2273
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38850089 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111717 $b ABA008
999    __
$a ok $b bmc $g 2201783 $s 1231132
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 46 $c 9 $d 2261-2273 $e 20240608 $i 1097-0347 $m Head & neck $n Head Neck $x MED00001983
GRA    __
$a 315941-01 $p Cancer Research UK $2 United Kingdom
GRA    __
$p Italian Ministry of Health "Ricerca Corrente."
GRA    __
$a 825771 $p European Union's Horizon 2020 research and innovation programme
GRA    __
$a 0180142s08 $p Estonian Ministry of Education and Research
GRA    __
$p University of Athens Medical School
GRA    __
$p Compagnia San Paolo, AIRC
GRA    __
$a 001 $p World Health Organization $2 International
GRA    __
$a QLK1-CT-2001-00182 $p European Community (5th Framework Programme)
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace